• "Любовь должна победить на земле. А если не победит, то Ее поражение все равно станет победой." Монах Симеон Афонский.

Терапевтическая польза куркумина: клинические испытания (2)

Мелания

Руководитель школы TROPOS
Команда форума
(продолжение)

СПИД

Не было обнаружено никаких свидетельств снижения, связанного с куркумином вирусной нагрузки. Несмотря на отсутствие видимых антивирусных, большинству участников нравилось принимать куркумин, потому что они чувствовали себя лучше . Вероятно, куркумин может обеспечить преимущества неизвестными способами (66).

β-талассемия

Авторы этого исследования пришли к выводу, что куркуминоиды эффективны против окислительного стресса у пациентов с β-талассемией. Тем не менее, необходимы дальнейшие исследования (67).

Дискинезия желчевыводящих путей

Исследование показало, что уменьшение боли было более быстрым в течение первой недели лечения у пациентов, получавших экстракт куркумы, чем в контрольной группе. Такие симптомы как пищевая непереносимость, тошнота, рвота и метеоризм, также были улучшены у пациентов, получавших экстракт, в течение всего периода лечения. Не наблюдалось никаких побочных эффектов (68).

Сократительная способность желчного пузыря

Результаты исследования свидетельствуют о способности куркумина стимулировать сокращение желчного пузыря и снижать риск образования желчных камней (69).

Рецидивирующие ОРВИ

Через 4 недели приема лактоферрина и куркумина наблюдалось уменьшение количества ОРВИ и благоприятный иммуномодулирующий эффект у детей (70).

Гепатотоксичноть, вызванная приемом противотуберкулезных препаратов

Исследование показало, что в группе пациенто, принимавших куркумин, отмечались снижение уровня трансаминаз и билирубина, СОЭ, значительная прибавка в весе у пациентов. Авторы этого исследования пришли к выводу, что куркума может использоваться в качестве адъювантнй терапии для предотвращения гепатотоксичности, вызванной приемом противотуберкулезных препаратов (71).

Хроническое отравление мышьяком

Загрязнение мышьяком подземных вод является глобальной угрозой для здоровья человека. Самые большие случаи загрязнения подземных вод мышьяком зарегистрированы в Бангладеш и Западной Бенгалии в Индии. Канцерогенные эффекты мышьяка, вероятно, опосредуются путем окислительного повреждения ДНК. Три месяца приема куркумина уменьшили повреждение ДНК и и перекисное окисление липидов. Также было отмечено значительное повышение уровней таких антиоксидантов, как каталаза, супероксиддисмутаза, глутатионпероксидаза и глутатион. Авторы этого исследования пришли к выводу, что куркумин может играть некоторую защитную роль против повреждений ДНК, вызванных мышьяком (72).

Алкоголтная интоксикация

Недавно было обнаружено, что Теракурмин эффективен в терапии алкогольной интоксикации (73).

Хронический бактериальный простатит (ХБП)

В исследовании отмечено, что у пациентов, получавших куркумин дополнительно к антибиотикотерапии, наблюдались уменьшение количества рецидивов, ослабление симптомов ХБП и улучшение качества жизни по сравнению с пациентами, получавшими только антибиотикотерапию (74).

НЕБЛАГОПРИЯТНЫЕ ПОСЛЕДСТВИЯ ПРИЕМА КУРКУМИНА

В ряде исследований некоторые пациенты отмечали незначительный токсический эффект куркумина, который проявлялся диареей, головной болью, сыпью и желтым стулом и, предположительно, не связан с дозой (105).

В другом исследовании прием куркумина был связан с тошнотой и диареей и вызывал увеличение содержания щелочной фосфатазы в сыворотке и содержание лактатдегидрогеназы в крови у исследуемых (14).

В одном исследовании пациентов с прогрессирующим раком поджелудочной железы 5 из 17 пациентов, получавших куркумин в сочетании с гемцитабином, сообщили о сильной абдоминальной боли после приема куркумина от нескольких дней до 2 недель (20).

ВЫВОДЫ

Общим для всех этих исследований была безопасность, переносимость и нетоксичность этого полифенола даже при дозах до 8 г в день. Основным механизмом клинической эффективности куркумина, по-видимому, является модуляция многочисленных сигнальных молекул. Однако из-за сложного характера заболеваний основной механизм во многих случаях остается неясным.

Из результатов завершенных клинических испытаний может показаться, что клиническая эффективность куркумина слишком хороша, чтобы быть правдой. Однако этот полифенол еще не одобрен для использования человеком. Плохая биодоступность и ограниченные побочные эффекты, о которых сообщают некоторые исследователи, являются основным ограничением терапевтического использования куркумина.

ССЫЛКИ

1. Frantz S. Drug discovery: playing dirty. Nature. 2005;437(7061):942–943. doi: 10.1038/437942a.[PubMed] [Cross Ref]

2. Mencher SK, Wang LG. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue) BMC Clin Pharmacol. 2005;5(1):3. doi: 10.1186/1472-6904-5-3. [PMC free article] [PubMed] [Cross Ref]

3. Vogel A, Pelletier J. Examen chimique de la racine de Curcuma. J Pharm. 1815;1:289–300.

4. Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol. 2012;39(3):283–299. doi: 10.1111/j.1440-1681.2011.05648.x. [PMC free article] [PubMed] [Cross Ref]

5. Schraufstatter E, Bernt H. Antibacterial action of curcumin and related compounds. Nature. 1949;164(4167):456. doi: 10.1038/164456a0. [PubMed] [Cross Ref]

6. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2009;30(2):85–94. doi: 10.1016/j.tips.2008.11.002.[PubMed] [Cross Ref]

7. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009;41(1):40–59. doi: 10.1016/j.biocel.2008.06.010. [PMC free article] [PubMed][Cross Ref]

8. Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, Priyadarsini IK, et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep. 2011;28(12):1937–1955. doi: 10.1039/c1np00051a.[PMC free article] [PubMed] [Cross Ref]

9. Loeber CC. De curcuma officinarum. diss Inaug Halae. 1748.

10. Oppenheimer A. Turmeric (curcumin) in biliary diseases. Lancet. 1937;229:619–621. doi: 10.1016/S0140-6736(00)98193-5. [Cross Ref]

11. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol. 2011;68(1):157–164. doi: 10.1007/s00280-010-1470-2. [PubMed][Cross Ref]

12. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14(14):4491–4499. doi: 10.1158/1078-0432.CCR-08-0024. [PubMed] [Cross Ref]

13. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res. 2001;7(7):1894–1900. [PubMed]

14. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10(20):6847–6854. doi: 10.1158/1078-0432.CCR-04-0744. [PubMed] [Cross Ref]

15. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev. 2005;14(1):120–125. [PubMed]

16. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2006;4(8):1035–1038. doi: 10.1016/j.cgh.2006.03.020. [PubMed] [Cross Ref]

17. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 2011;4(3):354–364. doi: 10.1158/1940-6207.CAPR-10-0098. [PMC free article] [PubMed] [Cross Ref]

18. He ZY, Shi CB, Wen H, Li FL, Wang BL, Wang J. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Investig. 2011;29(3):208–213. doi: 10.3109/07357907.2010.550592. [PubMed] [Cross Ref]

19. Durgaprasad S, Pai CG, Vasanthkumar, Alvres JF, Namitha S. A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res. 2005;122(4):315–318. [PubMed]

20. Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer. 2010;62(8):1137–1141. doi: 10.1080/01635581.2010.513802.[PubMed] [Cross Ref]

21. Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther. 2010;9(1):8–14. doi: 10.4161/cbt.9.1.10392. [PubMed] [Cross Ref]

22. Ide H, Tokiwa S, Sakamaki K, Nishio K, Isotani S, Muto S, et al. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate. 2010;70(10):1127–1133. doi: 10.1002/pros.21147. [PubMed] [Cross Ref]

23. Golombick T, Diamond TH, Badmaev V, Manoharan A, Ramakrishna R. The potential role of curcumin in patients with monoclonal gammopathy of undefined significance–its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker. Clin Cancer Res. 2009;15(18):5917–5922. doi: 10.1158/1078-0432.CCR-08-2217. [PubMed] [Cross Ref]

24. Vadhan-Raj S, Weber D, Wang M, Giralt S, Alexanian R, Thomas S, et al. Curcumin downregulates NF-КB and related genes in patients with multiple myeloma: results of a phase 1/2 study. Blood. 2007;110(11):357a.

25. Polasa K, Raghuram TC, Krishna TP, Krishnaswamy K. Effect of turmeric on urinary mutagens in smokers. Mutagenesis. 1992;7(2):107–109. doi: 10.1093/mutage/7.2.107. [PubMed] [Cross Ref]

26. Kuttan R, Sudheeran PC, Josph CD. Turmeric and curcumin as topical agents in cancer therapy. Tumori. 1987;73(1):29–31. [PubMed]

27. Hastak K, Lubri N, Jakhi SD, More C, John A, Ghaisas SD, et al. Effect of turmeric oil and turmeric oleoresin on cytogenetic damage in patients suffering from oral submucous fibrosis. Cancer Lett. 1997;116(2):265–269. doi: 10.1016/S0304-3835(97)00205-X. [PubMed] [Cross Ref]

28. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21(4B):2895–2900. [PubMed]

29. Chainani-Wu N, Silverman S, Jr, Reingold A, Bostrom A, Mc Culloch C, Lozada-Nur F, et al. A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus. Phytomedicine. 2007;14(7–8):437–446. doi: 10.1016/j.phymed.2007.05.003. [PubMed] [Cross Ref]

30. Rai B, Kaur J, Jacobs R, Singh J. Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress. J Oral Sci. 2010;52(2):251–256. doi: 10.2334/josnusd.52.251. [PubMed] [Cross Ref]

31. Kim SG, Veena MS, Basak SK, Han E, Tajima T, Gjertson DW, et al. Curcumin treatment suppresses IKKbeta kinase activity of salivary cells of patients with head and neck cancer: a pilot study. Clin Cancer Res. 2011;17(18):5953–5961. doi: 10.1158/1078-0432.CCR-11-1272. [PMC free article] [PubMed][Cross Ref]

32. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005;50(11):2191–2193. doi: 10.1007/s10620-005-3032-8. [PubMed] [Cross Ref]

33. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4(12):1502–1506. doi: 10.1016/j.cgh.2006.08.008. [PubMed] [Cross Ref]

34. Lahiff C, Moss AC. Curcumin for clinical and endoscopic remission in ulcerative colitis. Inflamm Bowel Dis. 2011;17(7):E66. doi: 10.1002/ibd.21710. [PubMed] [Cross Ref]

35. Epstein J, Docena G, MacDonald TT, Sanderson IR. Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. Br J Nutr. 2010;103(6):824–832. doi: 10.1017/S0007114509992510. [PubMed] [Cross Ref]

36. Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med. 2004;10(6):1015–1018. doi: 10.1089/acm.2004.10.1015. [PubMed] [Cross Ref]

37. Shimouchi A, Nose K, Takaoka M, Hayashi H, Kondo T. Effect of dietary turmeric on breath hydrogen. Dig Dis Sci. 2009;54(8):1725–1729. doi: 10.1007/s10620-008-0550-1. [PubMed] [Cross Ref]

38. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane) Indian J Med Res. 1980;71:632–634. [PubMed]

39. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res. 2012;26(11):1719–25. doi:10.1002/ptr.4639. [PubMed]

40. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, et al. Product-evaluation registry of Meriva(R), a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva Med. 2010;52(2 Suppl 1):55–62. [PubMed]

41. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, et al. Efficacy and safety of Meriva(R), a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev. 2010;15(4):337–344. [PubMed]

42. Lal B, Kapoor AK, Asthana OP, Agrawal PK, Prasad R, Kumar P, et al. Efficacy of curcumin in the management of chronic anterior uveitis. Phytother Res. 1999;13(4):318–322. doi: 10.1002/(SICI)1099-1573(199906)13:4<318::AID-PTR445>3.0.CO;2-7. [PubMed] [Cross Ref]

43. Allegri P, Mastromarino A, Neri P. Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment. Long-term follow-up. Clin Ophthalmol. 2010;4:1201–1206.[PMC free article] [PubMed]

44. Satoskar RR, Shah SJ, Shenoy SG. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol. 1986;24(12):651–654. [PubMed]

45. Kositchaiwat C, Kositchaiwat S, Havanondha J. Curcuma longa Linn. in the treatment of gastric ulcer comparison to liquid antacid: a controlled clinical trial. J Med Assoc Thail. 1993;76(11):601–605. [PubMed]

46. Prucksunand C, Indrasukhsri B, Leethochawalit M, Hungspreugs K. Phase II clinical trial on effect of the long turmeric (Curcuma longa Linn) on healing of peptic ulcer. Southeast Asian J Trop Med Public Health. 2001;32(1):208–215. [PubMed]

47. Di Mario F, Cavallaro LG, Nouvenne A, Stefani N, Cavestro GM, Iori V, et al. A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? Helicobacter. 2007;12(3):238–243. doi: 10.1111/j.1523-5378.2007.00497.x. [PubMed] [Cross Ref]

48. Koosirirat C, Linpisarn S, Changsom D, Chawansuntati K, Wipasa J. Investigation of the anti-inflammatory effect of Curcuma longa in Helicobacter pylori-infected patients. Int Immunopharmacol. 2010;10(7):815–818. doi: 10.1016/j.intimp.2010.04.021. [PubMed] [Cross Ref]

49. Lal B, Kapoor AK, Agrawal PK, Asthana OP, Srimal RC. Role of curcumin in idiopathic inflammatory orbital pseudotumours. Phytother Res. 2000;14(6):443–447. doi: 10.1002/1099-1573(200009)14:6<443::AID-PTR619>3.0.CO;2-V. [PubMed] [Cross Ref]

50. Asawanonda P, Klahan SO. Tetrahydrocurcuminoid cream plus targeted narrowband UVB phototherapy for vitiligo: a preliminary randomized controlled study. Photomed Laser Surg. 2010;28(5):679–684. doi: 10.1089/pho.2009.2637. [PubMed] [Cross Ref]

51. Heng MC, Song MK, Harker J, Heng MK. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol. 2000;143(5):937–949. doi: 10.1046/j.1365-2133.2000.03767.x. [PubMed][Cross Ref]

52. Kurd SK, Smith N, VanVoorhees A, Troxel AB, Badmaev V, Seykora JT, et al. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. J Am Acad Dermatol. 2008;58(4):625–631. doi: 10.1016/j.jaad.2007.12.035. [PMC free article] [PubMed] [Cross Ref]

53. Burns J, Joseph PD, Rose KJ, Ryan MM, Ouvrier RA. Effect of oral curcumin on Dejerine-Sottas disease. Pediatr Neurol. 2009;41(4):305–308. doi: 10.1016/j.pediatrneurol.2009.04.030. [PubMed][Cross Ref]

54. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer’s disease. Curr Alzheimer Res. 2005;2(2):131–136. doi: 10.2174/1567205053585882. [PMC free article] [PubMed] [Cross Ref]

55. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol. 2008;28(1):110–113. doi: 10.1097/jcp.0b013e318160862c. [PubMed] [Cross Ref]

56. Alwi I, Santoso T, Suyono S, Sutrisna B, Suyatna FD, Kresno SB, et al. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta Med Indones. 2008;40(4):201–210. [PubMed]

57. Soni KB, Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol. 1992;36(4):273–275. [PubMed]

58. Srinivasan M. Effect of curcumin on blood sugar as seen in a diabetic subject. Indian J Med Sci. 1972;26(4):269–270. [PubMed]

59. Usharani P, Mateen AA, Naidu MU, Raju YS, Chandra N. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R D. 2008;9(4):243–250. doi: 10.2165/00126839-200809040-00004. [PubMed] [Cross Ref]

60. Wickenberg J, Ingemansson SL, Hlebowicz J. Effects of Curcuma longa (turmeric) on postprandial plasma glucose and insulin in healthy subjects. Nutr J. 2010;9:43. doi: 10.1186/1475-2891-9-43.[PMC free article] [PubMed] [Cross Ref]

61. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care. 2012;35(11):2121–7. doi:10.2337/dc12-0116. [PMC free article] [PubMed]

62. Khajehdehi P, Pakfetrat M, Javidnia K, Azad F, Malekmakan L, Nasab MH, et al. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-beta and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol. 2011;45(5):365–370. doi: 10.3109/00365599.2011.585622. [PubMed] [Cross Ref]

63. Appendino G, Belcaro G, Cornelli U, Luzzi R, Togni S, Dugall M, et al. Potential role of curcumin phytosome (Meriva) in controlling the evolution of diabetic microangiopathy. A pilot study. Panminerva Med. 2011;53(3 Suppl 1):43–49. [PubMed]

64. Khajehdehi P, Zanjaninejad B, Aflaki E, Nazarinia M, Azad F, Malekmakan L, et al. Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. J Ren Nutr. 2012;22(1):50–57. doi: 10.1053/j.jrn.2011.03.002. [PubMed] [Cross Ref]

65. Shoskes D, Lapierre C, Cruz-Correa M, Muruve N, Rosario R, Fromkin B, et al. Beneficial effects of the bioflavonoids curcumin and quercetin on early function in cadaveric renal transplantation: a randomized placebo controlled trial. Transplantation. 2005;80(11):1556–1559. doi: 10.1097/01.tp.0000183290.64309.21.[PubMed] [Cross Ref]

66. James JS. Curcumin: clinical trial finds no antiviral effect. AIDS Treat News. 1996;(no 242):1–2.[PubMed]

67. Kalpravidh RW, Siritanaratkul N, Insain P, Charoensakdi R, Panichkul N, Hatairaktham S, et al. Improvement in oxidative stress and antioxidant parameters in beta-thalassemia/Hb E patients treated with curcuminoids. Clin Biochem. 2010;43(4–5):424–429. doi: 10.1016/j.clinbiochem.2009.10.057. [PubMed][Cross Ref]

68. Niederau C, Gopfert E. The effect of chelidonium- and turmeric root extract on upper abdominal pain due to functional disorders of the biliary system. Results from a placebo-controlled double-blind study. Med Klin (Munich) 1999;94(8):425–430. doi: 10.1007/BF03044726. [PubMed] [Cross Ref]

69. Rasyid A, Lelo A. The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther. 1999;13(2):245–249. doi: 10.1046/j.1365-2036.1999.00464.x. [PubMed][Cross Ref]

70. Zuccotti GV, Trabattoni D, Morelli M, Borgonovo S, Schneider L, Clerici M. Immune modulation by lactoferrin and curcumin in children with recurrent respiratory infections. J Biol Regul Homeost Agents. 2009;23(2):119–123. [PubMed]

71. Adhvaryu MR, Reddy N, Vakharia BC. Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach. World J Gastroenterol. 2008;14(30):4753–4762. doi: 10.3748/wjg.14.4753.[PMC free article] [PubMed] [Cross Ref]

72. Biswas J, Sinha D, Mukherjee S, Roy S, Siddiqi M, Roy M. Curcumin protects DNA damage in a chronically arsenic-exposed population of West Bengal. Hum Exp Toxicol. 2010;29(6):513–524. doi: 10.1177/0960327109359020. [PubMed] [Cross Ref]

73. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, et al. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011;34(5):660–665. doi: 10.1248/bpb.34.660. [PubMed] [Cross Ref]

74. Cai T, Mazzoli S, Bechi A, Addonisio P, Mondaini N, Pagliai RC, et al. Serenoa repens associated with urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study. Int J Antimicrob Agents. 2009;33(6):549–553. doi: 10.1016/j.ijantimicag.2008.11.012. [PubMed] [Cross Ref]

75. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–818. doi: 10.1021/mp700113r. [PubMed] [Cross Ref]

76. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353–356. doi: 10.1055/s-2006-957450. [PubMed] [Cross Ref]

77. Gota VS, Maru GB, Soni TG, Gandhi TR, Kochar N, Agarwal MG. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem. 2010;58(4):2095–2099. doi: 10.1021/jf9024807. [PubMed] [Cross Ref]

78. Cuomo J, Appendino G, Dern AS, Schneider E, McKinnon TP, Brown MJ, et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod. 2011;74(4):664–669. doi: 10.1021/np1007262. [PubMed] [Cross Ref]

79. Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S. A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci. 2008;70(4):445–449. doi: 10.4103/0250-474X.44591. [PMC free article] [PubMed] [Cross Ref]

80. Disilvestro RA, Joseph E, Zhao S, Joshua B. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J. 2012;11(1):79. doi: 10.1186/1475-2891-11-79.[PMC free article] [PubMed] [Cross Ref]

81. Goel A, Jhurani S, Aggarwal BB. Multi-targeted therapy by curcumin: how spicy is it? Mol Nutr Food Res. 2008;52(9):1010–1030. doi: 10.1002/mnfr.200700354. [PubMed] [Cross Ref]

82. Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev. 2010;29(3):405–434. doi: 10.1007/s10555-010-9235-2. [PMC free article] [PubMed][Cross Ref]

83. Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford) 2008;10(1):58–62. doi: 10.1080/13651820701883148. [PMC free article] [PubMed][Cross Ref]

84. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Clin Lymphoma Myeloma. 2005;6(2):102–114. doi: 10.3816/CLM.2005.n.036. [PubMed] [Cross Ref]

85. Scully C, Beyli M, Ferreiro MC, Ficarra G, Gill Y, Griffiths M, et al. Update on oral lichen planus: etiopathogenesis and management. Crit Rev Oral Biol Med. 1998;9(1):86–122. doi: 10.1177/10454411980090010501. [PubMed] [Cross Ref]

86. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15(2):425–430. doi: 10.1158/1078-0432.CCR-08-0149. [PubMed] [Cross Ref]

87. Megraud F, Brassens-Rabbe MP, Denis F, Belbouri A, Hoa DQ. Seroepidemiology of Campylobacter pylori infection in various populations. J Clin Microbiol. 1989;27(8):1870–1873. [PMC free article][PubMed]

88. Birch-Hirschfeld A. Zur diagnostic and pathologic der orbital tumoren. Ber Dtsch Opthalmol Ges. 1905;32:127–135.

89. Orcutt JC, Garner A, Henk JM, Wright JE. Treatment of idiopathic inflammatory orbital pseudotumours by radiotherapy. Br J Ophthalmol. 1983;67(9):570–574. doi: 10.1136/bjo.67.9.570. [PMC free article][PubMed] [Cross Ref]

90. Schallreuter KU, Wood JM, Pittelkow MR, Buttner G, Swanson N, Korner C, et al. Increased monoamine oxidase A activity in the epidermis of patients with vitiligo. Arch Dermatol Res. 1996;288(1):14–18. doi: 10.1007/BF02505037. [PubMed] [Cross Ref]

91. Arca E, Tastan HB, Erbil AH, Sezer E, Koc E, Kurumlu Z. Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. J Dermatol. 2006;33(5):338–343. doi: 10.1111/j.1346-8138.2006.00079.x. [PubMed] [Cross Ref]

92. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741. doi: 10.1001/jama.296.14.1735. [PubMed][Cross Ref]

93. Reddy S, Aggarwal BB. Curcumin is a non-competitive and selective inhibitor of phosphorylase kinase. FEBS Lett. 1994;341(1):19–22. doi: 10.1016/0014-5793(94)80232-7. [PubMed] [Cross Ref]

94. Mattson MP, Rydel RE. Alzheimer’s disease. Amyloid ox-tox transducers. Nature. 1996;382(6593):674–675. doi: 10.1038/382674a0. [PubMed] [Cross Ref]

95. Goyal A, Petersen JL, Mahaffey KW. The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes. Curr Cardiol Rep. 2004;6(4):300–307. doi: 10.1007/s11886-004-0080-1. [PubMed] [Cross Ref]

96. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340(2):115–126. doi: 10.1056/NEJM199901143400207. [PubMed] [Cross Ref]

97. Sathyapalan T, Atkin SL. Is there a role for immune and anti-in-flammatory therapy in type 2 diabetes? Minerva Endocrinol. 2011;36(2):147–156. [PubMed]

98. Camera A, Hopps E, Caimi G. Diabetic microangiopathy: physiopathological, clinical and therapeutic aspects. Minerva Endocrinol. 2007;32(3):209–229. [PubMed]

99. Shoskes DA, Shahed AR, Kim S. Delayed graft function. Influence on outcome and strategies for prevention. Urol Clin N Am. 2001;28(4):721–732. doi: 10.1016/S0094-0143(01)80028-8. [PubMed][Cross Ref]

100. Fibach E, Rachmilewitz E. The role of oxidative stress in hemolytic anemia. Curr Mol Med. 2008;8(7):609–619. doi: 10.2174/156652408786241384. [PubMed] [Cross Ref]

101. Marzio L. Factors affecting gallbladder motility: drugs. Dig Liver Dis. 2003;35(Suppl 3):S17–S19. doi: 10.1016/S1590-8658(03)00088-4. [PubMed] [Cross Ref]

102. Wagenlehner FM, Diemer T, Naber KG, Weidner W. Chronic bacterial prostatitis (NIH type II): diagnosis, therapy and influence on the fertility status. Andrologia. 2008;40(2):100–104. doi: 10.1111/j.1439-0272.2007.00827.x. [PubMed] [Cross Ref]

103. Nickel JC, Xiang J. Clinical significance of nontraditional bacterial uropathogens in the management of chronic prostatitis. J Urol. 2008;179(4):1391–1395. doi: 10.1016/j.juro.2007.11.081. [PubMed] [Cross Ref]

104. Rodwell C. Curcumin curries favour? Nat Rev Cancer. 2012;12(6):376. doi: 10.1038/nrc3288.[Cross Ref]

105. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6:10. doi: 10.1186/1472-6882-6-10.[PMC free article] [PubMed] [Cross Ref]



.
 
Сверху